Leslie V. Norwalk
CIK: 0001533568
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (24 total)
- Jul 29, 2026NBIX
NEUROCRINE BIOSCIENCES INC
Exercise(M)Direct842 shares at avg. $139.43$117K - Jul 28, 2026NBIX
NEUROCRINE BIOSCIENCES INC
Sale(S)Direct1.3K shares at avg. $182.01$228K - Jun 24, 2026ARVN
ARVINAS, INC.
Award(A)Direct15.5K shares- - Jun 4, 2026NBIX
NEUROCRINE BIOSCIENCES INC
Sale(S)Direct1.3K shares at avg. $168.06$210K - May 27, 2026NBIX
NEUROCRINE BIOSCIENCES INC
Award(A)DirectRestriced Stock Unit
1.3K shares- - May 27, 2026NBIX
NEUROCRINE BIOSCIENCES INC
Award(A)DirectNon-Qualified Stock Option
2.6K shares- - May 21, 2026NBIX
NEUROCRINE BIOSCIENCES INC
Exercise(M)Direct1.7K shares- - May 14, 2026CVS
CVS HEALTH Corp
Award(A)Direct1.4K shares at avg. $97.15$141K - May 12, 2026NBIX
NEUROCRINE BIOSCIENCES INC
Sale(S)Direct3.8K shares at avg. $155.01$591K - Jan 21, 2026GMED
GLOBUS MEDICAL INC
Award(A)DirectStock Option (Right to Buy Class A Common Stock)
15K shares- - Jan 8, 2026GMED
GLOBUS MEDICAL INC
Sale(S)Direct2K shares at avg. $101.10$202K - Dec 16, 2025NBIX
NEUROCRINE BIOSCIENCES INC
Sale(S)Direct1.2K shares at avg. $155.09$185K - Dec 15, 2025NBIX
NEUROCRINE BIOSCIENCES INC
Sale(S)Direct5K shares at avg. $152.23$761K - Dec 15, 2025NBIX
NEUROCRINE BIOSCIENCES INC
Exercise(M)Direct1.7K shares at avg. $84.95$146K - Dec 15, 2025NBIX
NEUROCRINE BIOSCIENCES INC
Exercise(M)Direct8.3K shares at avg. $92.35$764K - Dec 12, 2025GMED
GLOBUS MEDICAL INC
Sale(S)Direct4K shares at avg. $88.85$355K - Nov 20, 2025CVS
CVS HEALTH Corp
Award(A)Direct1.7K shares at avg. $76.04$126K - Jun 25, 2025ARVN
ARVINAS, INC.
Award(A)Direct16K shares- - May 22, 2025NBIX
NEUROCRINE BIOSCIENCES INC
Exercise(M)Direct1.4K shares- - May 21, 2025NBIX
NEUROCRINE BIOSCIENCES INC
Award(A)DirectRestricted Stock Unit
1.7K shares- - May 21, 2025NBIX
NEUROCRINE BIOSCIENCES INC
Award(A)DirectNon-Qualified Stock Option
3.3K shares- - May 15, 2025CVS
CVS HEALTH Corp
Award(A)Direct2.1K shares at avg. $60.47$126K - Jan 23, 2025GMED
GLOBUS MEDICAL INC
Award(A)DirectStock Option (Right to Buy Class A Common Stock)
15K shares- - Nov 21, 2024CVS
CVS HEALTH Corp
Award(A)Direct2.2K shares at avg. $57.10$126K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 29, 2026 |  NBIX NEUROCRINE BIOSCIENCES INC | Exercise(M) | 842 | $139.43 | $117,400 | Direct |
| Jul 28, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | Sale(S) | 1,250 | $182.01 | $227,508 | Direct |
| Jun 24, 2026 |  ARVN ARVINAS, INC. | Award(A) | 15,527 | - | $0 | Direct |
| Jun 4, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | Sale(S) | 1,250 | $168.06 | $210,072 | Direct |
| May 27, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | Award(A) Restriced Stock Unit | 1,284 | - | - | Direct |
| May 27, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | Award(A) Non-Qualified Stock Option | 2,624 | - | - | Direct |
| May 21, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | Exercise(M) | 1,659 | - | $0 | Direct |
| May 14, 2026 |  CVS CVS HEALTH Corp | Award(A) | 1,447 | $97.15 | $140,576 | Direct |
| May 12, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | Sale(S) | 3,810 | $155.01 | $590,601 | Direct |
| Jan 21, 2026 |  GMED GLOBUS MEDICAL INC | Award(A) Stock Option (Right to Buy Class A Common Stock) | 15,000 | - | - | Direct |
| Jan 8, 2026 | GMED GLOBUS MEDICAL INC | Sale(S) | 2,000 | $101.10 | $202,200 | Direct |
| Dec 16, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | Sale(S) | 1,190 | $155.09 | $184,558 | Direct |
| Dec 15, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | Sale(S) | 5,000 | $152.23 | $761,144 | Direct |
| Dec 15, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | Exercise(M) | 1,724 | $84.95 | $146,454 | Direct |
| Dec 15, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | Exercise(M) | 8,276 | $92.35 | $764,289 | Direct |
| Dec 12, 2025 | GMED GLOBUS MEDICAL INC | Sale(S) | 4,000 | $88.85 | $355,400 | Direct |
| Nov 20, 2025 | CVS CVS HEALTH Corp | Award(A) | 1,652 | $76.04 | $125,618 | Direct |
| Jun 25, 2025 | ARVN ARVINAS, INC. | Award(A) | 16,025 | - | - | Direct |
| May 22, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | Exercise(M) | 1,435 | - | - | Direct |
| May 21, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | Award(A) Restricted Stock Unit | 1,659 | - | - | Direct |
| May 21, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | Award(A) Non-Qualified Stock Option | 3,305 | - | - | Direct |
| May 15, 2025 | CVS CVS HEALTH Corp | Award(A) | 2,077 | $60.47 | $125,596 | Direct |
| Jan 23, 2025 | GMED GLOBUS MEDICAL INC | Award(A) Stock Option (Right to Buy Class A Common Stock) | 15,000 | - | - | Direct |
| Nov 21, 2024 | CVS CVS HEALTH Corp | Award(A) | 2,200 | $57.10 | $125,620 | Direct |
1-24 of 24 transactions
About Norwalk Leslie V
Norwalk Leslie V (SEC CIK 0001533568) files insider reports with the SEC as Director of NEUROCRINE BIOSCIENCES INC (NBIX), Director of ARVINAS, INC. (ARVN) and Director of CVS HEALTH Corp (CVS). Signal8 also holds filings tied to 1 other company.
Signal8 holds 18 ownership filings by Norwalk Leslie V (1 Form 3, 17 Form 4), filed between Nov 25, 2024 and Jul 30, 2026. Those filings report 24 transactions, from Nov 21, 2024 to Jul 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Norwalk Leslie V's filings is in SAN DIEGO, CA.
Recent filings by Norwalk Leslie V
- Jul 29, 2026: Option exercise of NBIX shares (Form 4, code M).
- Jul 28, 2026: Open-market sale of NBIX shares (Form 4, code S).
- Jun 24, 2026: Grant or award of ARVN shares (Form 4, code A).
- Jun 4, 2026: Open-market sale of NBIX shares (Form 4, code S).
- May 27, 2026: Grants or awards of NBIX derivative securities (2 lines, Form 4, code A).
Other insiders filing for NEUROCRINE BIOSCIENCES INC (NBIX)
- ROBERTS EIRY, Chief Medical Officer
- Onyia Jude, Chief Scientific Officer
- Lippoldt Darin, Chief Legal Officer
- Keswani Sanjay Chandru, Chief Medical Officer
- GORMAN KEVIN CHARLES, Director
- Gano Kyle, Chief Executive Officer